Zealand Pharma carries out Phase 1 clinical trial for SBS treatment
Category: #health  By Pankaj Singh  Date: 2019-06-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Zealand Pharma carries out Phase 1 clinical trial for SBS treatment

ZP7570 may be regarded as the next gen in the treatment and will help the SBS patients worldwide to understand the full potential of intestinal rehabilitation.

The Denmark based- Zealand Pharma, a biotechnology company involved in the discovery and development of peptide-based medicines has reportedly announced the dosing of the first subject in Phase 1 clinical trial of ZP7570, a potential treatment for SBS (short bowel syndrome).

As per trusted sources, ZP7570 is a dual GLP-1 / GLP-2 peptide medication that aims at managing and curing SBS. It may be regarded as the next gen in the treatment and will help the SBS patients worldwide to understand the full potential of intestinal rehabilitation.

For the record, GLP-2 improves the absorbing capacity of the intestines, while, GLP -1 apparently reduces the gastrointestinal motility. The medicinal properties in ZP7570 may allow the treatment of other gastrointestinal diseases.

Adam Steensberg, Executive Vice President and Chief Medical and Development officer, Zealand Pharma was quoted stating that the company is determined to change the lives of people affected with SBS.  Additionally, the company also seeks positive results from its Phase 3 clinical trial with glepaglutide, a best-in-class long-acting GLP-2 analog for the treatment of the syndrome. The initiation of the first phase trial with ZP7570, a dual GLP-1 / GLP-2 acting peptide, will mark an extremely important step taken by Zealand to innovate and discover medications in the effective treatment of SBS for patients, he further claimed.

Reportedly, SBS is a critical condition associated with complete loss of intestinal function. Patients are usually connected to pumps and infusion lines everyday, which further restricts the person’s ability to carry out daily activities. The patients diagnosed with SBS are prone to life-threatening diseases like liver damage, blood clots, sepsis and renal impairment.

Zealand Pharma’s clinical study is a double bind, placebo-controlled and single dose trial on 64 healthy subjects, randomized to ZP7570, the properties of which may also allow for therapeutic opportunities in many other gastrointestinal devises.

Source Credits https://www.nasdaq.com/press-release/zealand-pharma-doses-first-subject-in-phase-1-clinical-trial-with-potential-next-generation-20190626-00028



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

RADLogics obtains FDA's approval for AI-based chest X-Ray App
RADLogics obtains FDA's approval for AI-based chest X-Ray App
By Pankaj Singh

RADLogics Inc., a healthcare software company developing AI-powered solutions has reportedly received 510(k) clearance from the US FDA (Food and Drug Administration) for its latest AI-Powered chest X-ray pneumothorax a...

CDE of China NMPA clears I-Mab’s application for lemzoparlimab
CDE of China NMPA clears I-Mab’s application for lemzoparlimab
By Pankaj Singh

Clinical stage biopharmaceutical major, I-Mab, has reportedly announced that it has received the clearance of the Center for Drug Evaluation of the China National Medical Products Administration for its IND application...

Aoyuan Healthy to acquire 55% equity interest in Liantianmei
Aoyuan Healthy to acquire 55% equity interest in Liantianmei
By Pankaj Singh

Aoyuan Healthy Life Group Company Ltd., a renowned commercial property operation service and property management service provider based in China, has reportedly announced that Guangdong Xinyuerong Industrial Investment...